Skip to main content
. 2019 Apr 15;6(1):MMT13. doi: 10.2217/mmt-2018-0009

Table 5. . Characteristics of patients with and without immune-mediated adverse event.

Patient characteristics Affected (n = 15) Not affected (n = 36) p-value
Age 64.5 63.6 0.846

Gender 73.3% 75.0% 0.906

Overall survival (median) 20.6 months;
95% CI: 10.9–30.3
11.1 months;
95% CI: 7.8–14.5
0.030

Progression-free survival (median) 16.7 months;
95% CI: 6.9–26.6
6.38 months;
95% CI: 3.7–9.1
0.041